AKT1 and non-small cell lung carcinoma: This signature has proven instrumental in predicting the onset of resistance to treatments with EGFR-TKIs and PI3K/Akt inhibitors in various non-small cell lung cancer (NSCLC) cell lines and clinical specimens.